Cipla Ltd Share Price Today - Cipla Ltd Stock Price Live NSE/BSE

Cipla Ltd

NSE: CIPLA BSE: 500087

₹1329.50

(-0.30%)

Thu, 19 Mar 2026, 03:45 pm

MTF 5xInvest in Cipla Ltd with 5x Leverage Buy with MTF

Market Cap1076.85B

PE Ratio23.63

Dividend0.98

Health Technology

Pharmaceuticals: Other

24.5K

Cipla Share Price Live Chart

1 Day

0 (0%)

No Result Found

Summary

Market Cap
102442.75
Net Profit
5291.05
P/B
3.73
Sector P/E
31.95
P/E
22.08
EV/EBITDA
14.53
Debt/Equity (Industry)
0.16
Interest Cover (Industry)
17.01
ROCE (Industry)
16.41
RONW (Industry)
14.52
ROE
18.28
ROCE
23.15
Debt/Equity
0.02
EPS (TTM)
58.86
Dividend Yield
1.26
Book Value
407.52
Interest Cover
111

Analysis

all

Pros

Dividends per share have increased over the past 10 years.
Dividends paid are well covered by earnings (6.4x coverage).
Dividends after 3 years are expected to be well covered by earnings (6.2x coverage).
Dividends per share have been stable in the past 10 years.
Cipla's earnings growth is expected to exceed the low risk savings rate of 7.2%.

Cons

Cipla's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.76%).
Cipla's dividend is below the markets top 25% of dividend payers in India (3.08%).
Cash flow for Cipla is expected to decrease over the next 2 years.
Cipla's earnings are expected to grow by 17.6% yearly, however this is not considered high growth (20% yearly).
Cipla's earnings growth is positive but not above the India market average.

Financials

Ratios

Shareholders	DEC 2025	SEPT 2025	JUN 2025	MAR 2025	DEC 2024
Promoters	29.21	29.21	29.19	29.20	29.19
FII	23.93	24.54	25.24	26.28	26.65
DII	30.72	30.25	29.26	28.15	27.71
Public	16.13	15.99	16.30	16.37	16.44
Government	0.00	0.00	0.00	0.00	0.00

Technical Analysis

RSI

24.80

MACD

-22.19

50 DMA

1347.11

200 DMA

1480.93

Support and Resistance

Type	R3	R2	R1	PP	S1	S2	S3
Classic	1517.27	1429.07	1388.63	1340.87	1300.43	1252.67	1164.47
Fibonacci	1429.07	1395.37	1374.56	1340.87	1307.17	1286.36	1252.67
Camarilla	1372.46	1364.37	1356.29	1340.87	1340.12	1332.03	1323.94

Pivots Level: Classic

+176.40

1517.27

+88.20

1429.07

+47.77

1388.63

1340.87

Pivot Point

LTP: 1239.20

-40.43

1300.43

-88.20

1252.67

-176.40

1164.47

Moving Average

SMAEMA

Period

Value

10-EMA
1294.42
20-EMA
1313.04
30-EMA
1327.11
50-EMA
1354.63
100-EMA
1405.28
200-EMA
1447.59

Announcement Date	Purpose	Action	Ex Date
23 Jan 2026	board-meetings	Quarterly Results
30 Oct 2025	board-meetings	Quarterly Results
27 May 2025	dividend	Final Dividend - Rs. - 13	27 Jun 2025
13 May 2025	agm
13 May 2025	dividend	₹13.00 Dividend /Share	27 Jun 2025
02 Jul 2024	dividend	Final Dividend - Rs. - 13	02 Aug 2024
10 May 2024	dividend	₹13.00 Dividend /Share	02 Aug 2024
10 May 2024	agm
11 Jul 2023	agm
21 Jun 2023	dividend	Final Dividend - Rs. - 8.5	21 Jul 2023

Cipla Ltd

Dr Reddys Laboratories Ltd

Torrent Pharmaceuticals Ltd

Divis Laboratories Ltd

Lupin Ltd

Sun Pharmaceutical Industries Ltd

Cipla Ltd About

Cipla is in the business of manufacturing, developing, and marketing wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs). The Company has its wide network of manufacturing, trading and other incidental operations in India and International markets.

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln

Founded

1935

Headquarters

CEO

Y K Hamied

Employees

Contact

Website

http://www.cipla.com

cosecretary@cipla.com, contactus@cipla.com

Phone

91-22-24826000

Location

Cipla House Peninsula Buss Par, Ganpatrao Kadam Mg Lower Parel, Mumbai, Maharashtra, 400013

Year	History
2020	Completed phase-3 clinical study of generic asthma drug. Inked licensing pact with Gilead Sciences for potential COVID-19 treatment drug. Launched generic remdesivir for coronavirus patients. Collaborated with Stempeutics to launch Stempeucel for CLI treatment in India. Launched antibody detection kit for COVID-19 in India. Conferred Golden Peacock Global Award for Excellence in Corporate Governance 2020.
2021	Set up 30 MW solar plant in Maharashtra. Partnered with Alvotech to market biosimilars in Australia and New Zealand. Bagged National Energy Conservation Award 2021 in drug and pharmaceutical sector. Won Gold for Remdesivir in Covid Care Brand Category.
2022	Launched leuprolide acetate injection depot (22.5mg). Received USFDA approval for generic Revlimid (Lenalidomide Capsules). Launched child-friendly 4-in-1 antiretroviral treatment for HIV with DNDi in South Africa. Scored highest among pharma companies in CRISIL Sustainability Rating 2022. Won Frost & Sullivan and TERI Sustainability 4.0 Award.
2023	Acquired additional stake in GoApptiv Private Limited. Announced acquisition of South Africa-based Actor Pharma.
2024	Acquired additional shares in Achira Labs Private Limited. Merged Cipla Technologies LLC, USA with Cipla USA Inc. Announced joint venture in the US with Kemwell Biopharma and Manipal Education & Medical Group for cell therapy products.

Client Name	Order Side	QTY	Avg Price	Date
RUMANA HAMIED	Sell	4943250	1518.75	02 Dec 2024
SAMINA HAMIED	Sell	8954750	1518.75	02 Dec 2024
SHIRIN HAMIED	Sell	6363000	1345	15 May 2024
RUMANA HAMIED	Sell	4943250	1345	15 May 2024
ICICI PRUDENTIAL MUTUAL FUND	Buy	5525999	1345	15 May 2024
SAMINA HAMIED	Sell	8954750	1345	15 May 2024
Y K HAMIED	Sell	13446504	910.05	15 Feb 2022
M K HAMIED	Sell	6723252	910.15	15 Feb 2022

Cipla Ltd News

Cipla Allots 1,954 Equity Shares Under ESOS Schemes

Cipla Limited has allotted 1,954 equity shares under its employee stock option schemes, increasing paid-up share capital to INR 1,61,55,65,262 comprising 80,77,82,631 equity shares.

18 Mar 2026

companies

Cipla Block Trade Worth Rs. 57.04 Crores on NSE

Cipla witnessed a significant block trade on NSE involving 442,266 shares worth Rs. 57.04 crores at Rs. 1289.80 per share, indicating institutional investor activity.

17 Mar 2026

equity-markets

Cipla USA recalls Lanreotide Injection batches

Cipla's US subsidiary initiates recall of unexpired Lanreotide Injection batches, causing temporary market supply shortage following discussions with Pharmathen International.

09 Mar 2026

stocks

Cipla Forms JV with Kemwell for Biologics

Cipla announces 60:40 joint venture with Kemwell Biopharma to develop and market biologic products, with both partners investing up to 100 million rupees in the strategic partnership.

02 Mar 2026

co actions results

Cipla Incorporates Subsidiary in Saudi Arabia

Cipla Limited announces incorporation of wholly owned subsidiary 'Cipla Middle East Company' in Kingdom of Saudi Arabia for pharmaceutical manufacturing and distribution operations.

02 Mar 2026

co actions results

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

Version -5.76

Stocks:

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Explore

Calculators

Popular Calculators

Group Stocks

Others:

NSE BSE CDSL NSDL SEBI MCX MSEI NCDEX NSE IFSC INDIA INX Account Closure Form DP Investor Charter Broker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800

Cipla Ltd

Cipla Share Price Live Chart

Summary

Analysis

Financials

Ratios

Shareholding

Technical Analysis

Corporate Actions

Peer Comparison

Cipla Ltd About

Contact

Cipla Ltd Company History

Deals

Cipla Ltd News